Media ReleasesNext Science

View All Next Science News

Next Science - Oraderm Pharmaceuticals appointed as BlastX distributor

Sydney, Australia, Thursday, 19 May 2022: Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement for Australia and New Zealand with Oraderm Pharmaceuticals (Oraderm), a medical sales joint venture between Douglas Pharmaceuticals (New Zealand's largest privately owned pharmaceutical company) and Arrotex Pharmaceuticals (Australia’s largest privately owned pharmaceutical company), for the sale of Next Science’s antimicrobial wound gel, BlastX. 

The new distribution agreement grants Oraderm exclusive rights across Australia and New Zealand for the sale and marketing of a dual Next Science / Oraderm labelled version of BlastX. Revenues arising from the agreement are based on an agreed unit price and a minimum quantity per order. Next Science expects the revenues received from sales of BlastX to Oraderm to become material. 

The agreement term is 5 years and automatically extends for an additional period of 3 years subject to each party’s termination rights. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.